Regeneron led a $320m Series C round in Truveta.

Regeneron, a biopharmaceutical company, led a $320m Series C round in Truveta, a collective of US health systems delivering electronic health record data, with participation from Illumina. “Big Data – combined with human ingenuity – is the key to driving next-generation scientific advancements. For nearly four decades, Regeneron has discovered and developed groundbreaking medicines that address the underlying causes of disease, and this next frontier of medicine will continue to be driven by innovative application of data. By combining Regeneron’s expertise in genetics and drug development with Truveta's extensive phenotypic data and collaboration of leading U.S. health systems, we hope to create the ‘Big Data’ that will empower the next generation of drug discovery, as well as enable new approaches to healthcare analytics and healthcare management,” George D. Yancopoulos, Regeneron Board Co-Chair, President and Chief Scientific Officer.